Tempus AI Inc reports results for the quarter ended June 30 - Earnings Summary
Tempus AI Inc reports results for the quarter ended June 30 - Earnings Summary
Tempus AI Inc TEM.OQ reported a quarterly adjusted loss of 4 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -22 cents. The mean expectation of nineteen analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -23 cents to -7 cents per share.
Revenue rose 21.6% to $382.49 million from a year ago; analysts expected $379.74 million.
Tempus AI Inc's reported EPS for the quarter was 3 cents.
The company reported quarterly net income of $5.64 million.
Tempus AI Inc shares had fallen by 23.5% this quarter and lost 25.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 0.7% in the last three months.
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 7 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Tempus AI Inc is $67.00, about 33.9% above its last closing price of $44.29
This summary was machine generated from LSEG data July 31 at 07:54 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.14 | -0.04 | Beat |
Mar. 31 2026 | -0.19 | -0.13 | Beat |
Dec. 31 2025 | -0.04 | -0.04 | Met |
Sep. 30 2025 | -0.17 | -0.11 | Beat |
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb